Malta

Clinical assessment remains the foundation of dementia diagnosis in Malta. There is no evidence of a population-wide screening or systematic case-finding program, and detection is primarily opportunistic, arising from clinical encounters in primary or specialist care. Cognitive assessment forms a core component of specialist evaluation. The MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) have been translated and validated for use in the Maltese language, with the Maltese version referred to as MoCA-M. This suggests that standardized cognitive testing is embedded not only in clinical practice but also in pharmaceutical governance and reimbursement mechanisms.

Neuroimaging forms part of the specialist diagnostic work-up for dementia in Malta, particularly within hospital-based services led by Mater Dei Hospital. Structural imaging, most commonly computed tomography (CT) or magnetic resonance imaging (MRI), is generally used to exclude secondary causes of cognitive impairment and to support differential diagnosis once patients reach specialist care. While official dementia information materials do not provide modality-specific protocols, the availability of imaging within the public hospital system indicates that CT and MRI are accessible as part of standard specialist assessment rather than exceptional investigations. Positron emission tomography (PET), including amyloid or FDG PET, does not appear to be incorporated into routine national diagnostic pathways for dementia. There is no reference in policy documents or public guidance to PET as a standard diagnostic tool, suggesting that its use, if present at all, is highly limited, case-specific, or dependent on external referral arrangements rather than embedded within the public system. In December 2025, Mater Dei Hospital introduced one of two planned PET scanners for cancer patients, but its use for dementia or Alzheimer’s disease is not yet mentioned. Overall, imaging in Malta supports a conventional, exclusionary and confirmatory diagnostic model with innovative care models on route.

Genetic testing and risk stratification are not presented as routine elements of dementia diagnosis in Malta’s public policy framework. The strategy documents do not reference APOE genotyping or other genetic tests as part of standard diagnostic pathways, nor do they frame dementia care in terms of predictive or pre-symptomatic genetic risk management. This suggests that genetic considerations are confined to rare or atypical cases, such as suspected familial early onset dementia, and managed within specialist settings without national-level protocols. Overall, Malta’s approach remains firmly grounded in clinical assessment and functional diagnosis rather than in genomics-driven or personalized-medicine models

The National Dementia Strategy focuses primarily on system organization, awareness, timely clinical diagnosis, and post-diagnostic support rather than on advanced diagnostic technologies. There is no indication that cerebrospinal fluid biomarkers, blood-based biomarkers, or PET imaging are integrated into a nationwide protocol for dementia diagnosis. Where such tests are used, they are likely limited to selected cases within specialist hospital settings and dependent on clinical judgment rather than formal policy guidance. As a result, biomarker use in Malta appears to remain supplementary and case-specific rather than systemic.

Malta’s dementia care infrastructure is organized across a continuum of settings that combine acute medical assessment, rehabilitation, long-term residential care, and community-based mental health services. Government dementia information materials explicitly identify Mater Dei Hospital as the central acute and specialist hub, particularly for diagnosis, neurology outpatient follow-up, and access to hospital-based investigations. Rehabilitation and sub-acute care functions are associated with Karin Grech Rehabilitation Hospital, which plays a role in post-acute recovery and functional support for older adults, including those with cognitive impairment.

Long-term institutional care is anchored by San Vinċenz de Paul Residence, Malta’s largest state-run residential facility for older persons, where individuals with advanced dementia may reside when home-based care is no longer feasible. In parallel, Community Mental Health Teams provide outpatient psychiatric and psychological support, offering an additional access point for cognitive and behavioral assessment and follow-up. Together, these facilities reflect a system that is institutionally dense but highly centralized, with specialist expertise concentrated in a limited number of publicly run settings.

On the community and home care side, Malta operates a dedicated state service known as the Dementia Intervention Team. This multidisciplinary service is designed to support people living with dementia in their own homes and to stabilize care arrangements following diagnosis. Eligibility requires a confirmed dementia diagnosis and ongoing consultant follow-up, and access is initiated through specialist referral rather than self-enrollment. The service is described in official materials as free of charge, positioning it as a core public intervention rather than an optional or means-tested support. The Dementia Intervention Team typically focuses on functional assessment, caregiver guidance, behavioral management strategies, and coordination with other services. Its existence reflects a policy-level recognition that dementia care cannot be delivered solely through hospital or residential settings and that sustained community-based support is essential to delay institutionalization and reduce caregiver strain. However, access remains structured and clinically mediated, reinforcing the central role of specialist services even in community care delivery.

The costs of dementia treatment and ongoing care in Malta are shaped by a combination of public entitlements, formulary governance, and the degree of reliance on informal care. Pharmacological treatment within the public system is governed by the Government Formulary List (GFL), with eligible patients able to receive anti-dementia medicines free of charge through entitlement mechanisms such as Schedule V following formal diagnosis. This substantially reduces direct medication costs for patients whose treatment falls within approved formulary indications. ATTs are not covered at all.

Beyond medicines, non-pharmacological treatment and care costs vary more widely. Specialist follow-up, outpatient visits, and certain rehabilitation or community-based services provided through public institutions are typically covered, but the intensity and availability of structured post-diagnostic support are uneven. Long-term care costs, particularly for residential or institutional care settings such as San Vinċenz de Paul Residence, may involve means-tested contributions or co-payment arrangements depending on the individual’s financial circumstances. Home-based care, informal caregiving by family members, and privately arranged support services often represent significant hidden costs that are not fully captured by public expenditure.

As a result, Malta’s treatment and care cost profile reflects a system in which core medical treatment is strongly subsidized, while the longer-term social and caregiving dimensions of dementia generate substantial indirect and household-level costs. The financial burden therefore shifts over time from the health system to families, especially as disease severity increases and care needs become more intensive.

Caregiver support occupies a prominent place in Malta’s dementia policy framework. The National Dementia Strategy and related government presentations describe a structured support ecosystem that includes the National Dementia Helpline (1771), Dementia Activity Centres, the Dementia Intervention Team, and a dedicated dementia directorate function within government. These elements collectively signal an explicit recognition of caregiver burden as a systemic issue rather than a purely private family matter. The National Dementia Helpline serves as an accessible entry point for information, guidance, and signposting, while Dementia Activity Centres provide structured engagement for people with dementia and respite for caregivers. The presence of a dedicated dementia directorate further suggests institutionalization of dementia governance within the health and social care system. Nonetheless, despite this relatively comprehensive support architecture, much of the day-to-day burden of care continues to fall on families, with formal supports acting as supplements rather than substitutes for informal caregiving.

Malta currently operates under an active National Dementia Strategy for the period 2024–2031, titled Reaching New Heights, which was formally launched in February 2024. This strategy builds directly on Malta’s first National Dementia Strategy, which covered the years 2015-2023 and established the foundational architecture for dementia policy in the country. The continuation into a second strategy cycle signals that dementia is no longer treated as a time-limited pilot policy area, but as a permanent and evolving component of national health and social care planning. The 2024-2031 strategy positions itself as both a consolidation and an expansion of earlier policy commitments. It retains core principles introduced in the first strategy, such as person-centred care, awareness-raising, and caregiver support while explicitly updating priorities in response to demographic trends, system pressures, and implementation experience. The framing of the document emphasizes progression and maturation, suggesting a move from initial system building toward refinement, scaling, and quality improvement.

While the National Dementia Strategy 2024–2031 sets out an extensive programme of reforms across diagnosis, care, workforce development, and research, publicly available strategy documents do not specify a dedicated implementation budget. As a result, the extent to which future objectives will require additional funding remains unclear, particularly given projections showing a substantial increase in the number of people living with dementia in Malta over coming decades.

At the same time, Malta’s Strategy for Active Ageing (2023 – 2030) provides an overarching policy framework aimed at promoting health, independence, and social participation among older adults across the life course, with dementia positioned as a key intersecting challenge rather than an isolated condition. The strategy emphasizes prevention, wellbeing, and inclusion through measures that support healthy lifestyles, lifelong learning, community engagement, and age-friendly environments, while also strengthening links between health, social care, and community services. By encouraging older people to remain active contributors to society for as long as possible, the strategy seeks to delay functional decline, reduce avoidable dependency, and mitigate risk factors associated with cognitive impairment. In practice, it complements Malta’s National Dementia Strategy by addressing upstream determinants of cognitive health and by reinforcing the role of community-based services, informal caregivers, and supportive environments in enabling people to age with dignity, autonomy, and social connection.

Malta’s dementia policy framework recognizes the importance of psychosocial care as a core component of dementia management. Consistent with broader European practice, psychosocial interventions such as cognitive stimulation, social engagement activities, caregiver support, and person-centred care approaches are promoted to help maintain functioning, improve quality of life, and reduce caregiver burden. However, as in many European countries, the practical mechanisms for implementing, coordinating, and evaluating these interventions across health and social care services remain less clearly defined than clinical and medical aspects of dementia care.

Rather than signaling a forthcoming replacement strategy, the 2024-2031 plan is presented as a forward-looking framework designed to sustain momentum over the medium term. It is structured around multiple action areas, notably timely diagnosis, living well with dementia, workforce development, caregiver support, and coordination across health and social care. These priorities closely reflect lessons drawn from the implementation of the 2015-2023 strategy, which was subject to review and assessment prior to the launch of the new plan. The language used in public-facing materials emphasizes continuity and upgrading rather than policy rupture. The new strategy is explicitly informed by evaluation of previous objectives, stakeholder feedback, and observed gaps in service delivery. This creates a sense of policy momentum rather than episodic reform, with dementia positioned as a standing priority that will continue to be revisited, monitored, and adapted rather than reset at the end of each strategy cycle.

Among the most prominent initiatives is the National Dementia Helpline (1771), which functions as an accessible entry point for information, advice, and signposting. The helpline plays a critical role in bridging gaps between diagnosis, services, and caregiver needs, particularly for families navigating the system for the first time. It also reflects an emphasis on early engagement and ongoing support rather than crisis-only intervention.
The Dementia Intervention Team represents a more intensive form of structured support, delivering assistance directly within the home environment. Access to this service requires a confirmed diagnosis and consultant referral, underscoring its integration into the formal clinical pathway. Described as free of charge, the service focuses on stabilizing home care arrangements, supporting caregivers, and addressing functional and behavioral challenges in situ. Together with dementia activity centres, these initiatives form a layered post-diagnostic support structure that extends beyond purely medical care.

Recent studies estimate that a 2% population prevalence of dementia would be reached by 2025, around 25 years earlier than earlier projections suggested. The findings underscore a faster and more substantial rise in dementia prevalence in Malta than previously recognized, with important implications for health and social care planning.

To deal with dementia, the country has invested in a coordinated ecosystem that includes a national helpline, dementia activity centres, a dedicated community-based intervention team, and a multi-year national strategy with defined action areas. These initiatives represent organizational and governance innovation aimed at improving access, continuity of care, and caregiver support. Such innovations are system-level rather than clinical in nature, focusing on how services are delivered, coordinated, and sustained over time. In this sense, Malta’s approach reflects a model of social and organizational innovation, prioritizing scalability, equity, and integration over high-cost or high-technology solutions.

In May 2026, Malta expanded its community-based dementia care services through the opening of a new dementia day centre in Sliema, implemented as part of the National Dementia Strategy 2024–2031. The facility provides specialised therapeutic and psychosocial support, including sensory stimulation, reminiscence activities, social engagement programmes, and respite services for caregivers. Designed to support approximately 50 families, the centre aims to promote independence, improve quality of life, reduce caregiver burden, and enable people living with dementia to remain in their communities for longer. The opening also reflects Malta’s continued investment in non-pharmacological and person-centred approaches to dementia care through a growing network of dementia-specific day centres.

The Alzheimer’s Disease Research Group (ADRG) was established at the University of Malta in response to the growing recognition of dementia, particularly Alzheimer’s disease, as a major public health, social, and economic challenge. Despite limited resources, dementia research activity in Malta has expanded significantly, with most work concentrated at the University of Malta and conducted in collaboration with national and international institutions, including the International Institute on Ageing and public health authorities. Research spans biological, pharmacological, dietary, and social dimensions of dementia, alongside applied studies focused on care pathways and caregiver support. The ADRG was created to consolidate this multidisciplinary effort, promote collaboration in European and international research programs, and strengthen links between academic research, policy development, and civil-society organizations, positioning Malta as a small but active contributor to dementia research and system improvement.

In February 2018, the University of Malta announced a major research initiative targeting Alzheimer’s dementia and Parkinson’s disease, two neurodegenerative conditions affecting an estimated 8,000 people in Malta. Funded through the University’s Centre for Molecular Medicine & Biobanking and supported by private-sector contributions via the Research, Innovation and Development Trust (RIDT), the project aimed to advance understanding of how and why brain cells degenerate and to translate this knowledge into the development of new disease-modifying therapies. At the time, available treatments were limited to symptom management, underscoring the potential significance of the research. The three-year project (2018–2020) involved international collaboration with leading German research institutions, including the Max Planck Institute for Biophysical Chemistry and the German Centre for Neurodegenerative Diseases in Munich. A key research focus was the experimental compound anle138b, which showed potential to delay disease onset or slow progression in neurodegenerative disorders. The initiative highlighted Malta’s growing engagement in high-level biomedical research, the role of public–private partnerships in funding scientific innovation, and the University of Malta’s strategic emphasis on contributing to global research efforts with direct clinical relevance.

In September 2017, researchers at the University of Malta marked World Alzheimer’s Day by launching a research initiative focused on one of the most challenging aspects of dementia care: patient wandering. The study aimed to better understand wandering behaviors, identify the risks they pose to people with dementia, and develop practical technological solutions to support both patients and caregivers. The research specifically involved individuals in the early stages of dementia residing at St Vincent de Paul Residence, ensuring real-world relevance within a care setting. The project combined wearable devices and smart mobile technologies using pervasive electronic monitoring (PEM) to log and analyze individual wandering patterns. Research activities were carried out at the Mark Weiser Lab within the University of Malta’s Faculty of ICT, where simulations and human activity recognition methods were developed to improve real-time risk detection. Supported through collaboration between the university, St Vincent de Paul Residence, and Information Systems Limited via research funding mechanisms, the initiative sought to enhance quality of life technologies in dementia care. The study highlighted both the potential of assistive digital tools to improve safety and caregiver support, and the broader challenge posed by limited technological resources in hospitals and elderly care facilities.

A series of Alzheimer Europe podcasts, released in November 2014, explored emerging research on lifestyle and nutritional factors in relation to Alzheimer’s disease and dementia risk. In the first segment, a senior lecturer from the University of Malta discussed how nutrition may contribute to reducing the risk of developing Alzheimer’s disease, reflecting growing interest in modifiable risk factors within dementia prevention research. Subsequent vodcasts focused specifically on coffee consumption and cognitive health. An epidemiologist from Erasmus MC reviewed population-level epidemiological evidence linking coffee consumption with a reduced risk of Alzheimer’s disease and dementia, drawing on findings from a multi-year, externally funded research project. This was complemented by a presentation from a research director at INSERM, who examined the possible biological mechanisms underlying the relationship between coffee intake and cognitive decline. Together, the podcasts highlighted interdisciplinary and international research perspectives on diet, epidemiology, and brain health within the broader Alzheimer Europe knowledge-sharing platform.

A 2012 study published in the Malta Medical Journal presents updated prevalence estimates and projections for dementia in the Maltese islands, revising earlier figures that had underestimated the scale and speed of growth of the condition. Earlier estimates, based on the EURODEM project, suggested around 4,072 individuals with dementia in 2005, with numbers expected to nearly double by 2050. However, newer European prevalence data reviewed under the EUROCODE project produced higher and more refined age- and gender-specific rates. Applying these revised European prevalence rates, the study estimates that by 2010 there were approximately 5,198 individuals with dementia in Malta aged over 60, significantly more than previously projected. Looking ahead, the number of people with dementia over 60 is projected to approach 10,000 by 2030, representing around 2.3% of the total Maltese population.